SCHEMBL735154

SCHEMBL735154

CCCCCN(C)CCO

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR2 O95136 1/20 0.52
S1PR1 P21453 1/20 0.52
S1PR3 Q99500 1/20 0.52
S1PR5 Q9H228 1/20 0.52
DNM1 Q05193 3/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
GGPS1 O95749 4/20 0.47
FDPS P14324 1/20 0.47
AGTR1 P30556 1/20 0.47
OPRM1 P35372 1/20 0.47
PDE3A Q14432 1/20 0.47
LMNA P02545 2/20 0.46
ALDH1A1 P00352 2/20 0.46
HSD17B10 Q99714 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
TSHR P16473 1/20 0.46
KDM5A P29375 2/20 0.44
KDM4C Q9H3R0 2/20 0.44
KDM5C P41229 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7644317 0.97 S1PR2 (0.55) S1PR2S1PR1S1PR3S1PR5DNM1
SCHEMBL15563051 0.97 S1PR2 (0.55) S1PR2S1PR1S1PR3S1PR5DNM1
SCHEMBL15563633 0.97 S1PR2 (0.55) S1PR2S1PR1S1PR3S1PR5DNM1
SCHEMBL1036018 0.97 S1PR2 (0.55) S1PR2S1PR1S1PR3S1PR5DNM1
SCHEMBL15563255 0.97 S1PR2 (0.55) S1PR2S1PR1S1PR3S1PR5DNM1
SCHEMBL15563217 0.97 S1PR2 (0.55) S1PR2S1PR1S1PR3S1PR5DNM1
SCHEMBL7637086 0.97 S1PR2 (0.55) S1PR2S1PR1S1PR3S1PR5DNM1
SCHEMBL7090988 0.97 S1PR2 (0.55) S1PR2S1PR1S1PR3S1PR5DNM1
SCHEMBL7636037 0.97 S1PR2 (0.55) S1PR2S1PR1S1PR3S1PR5DNM1
SCHEMBL15563316 0.97 S1PR2 (0.55) S1PR2S1PR1S1PR3S1PR5DNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240231230-A1 COMPOSITION FOR FORMING SILICON-CONTAINING RESIST UNDERLAYER FILM NISSAN CHEMICAL CORPORATION (JP) 2024-07-11 US disclosed
WO-2024144829-A1 IONIC LIQUID CHAIN TRANSFER AGENT HALLIBURTON ENERGY SERVICES, INC. (US) 2024-07-04 WO disclosed
US-20230320995-A1 IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES CAPSTAN THERAPEUTICS, INC. (US) 2023-10-12 US disclosed
US-10558119-B2 Composition for coating resist pattern NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2020-02-11 US disclosed
US-20180149977-A1 COMPOSITION FOR COATING RESIST PATTERN NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2018-05-31 US disclosed
US-9748605-B2 Sulfur-containing additives for electrochemical or optoelectronic devices BASF SE (DE) 2017-08-29 US disclosed
EP-2748145-B1 SULFUR-CONTAINING ADDITIVES FOR ELECTROCHEMICAL OR OPTOELECTRONIC DEVICES BASF SE (DE) 2016-10-19 EP disclosed
US-9081142-B2 Photosensitive resin composition for a color filter and uses thereof CHI MEI CORPORATION (TW) 2015-07-14 US disclosed
US-20140346416-A1 PHOTOSENSITIVE RESIN COMPOSITION FOR A COLOR FILTER AND USES THEREOF CHI MEI CORPORATION (TW) 2014-11-27 US disclosed
US-20140193707-A1 SULFUR-CONTAINING ADDITIVES FOR ELECTROCHEMICAL OR OPTOELECTRONIC DEVICES BASF SE (DE) 2014-07-10 US disclosed
EP-0650476-A1 PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1995-05-03 EP disclosed
EP-0637298-A1 SUBSTITUTED CYCLOHEXENE-1,2-BICARBOXYLIC ACID DERIVATIVES AND RAW MATERIALS FOR PRODUCING THEM BASF Aktiengesellschaft (DE) 1995-02-08 EP disclosed
WO-1994022826-A1 PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-10-13 WO disclosed
EP-0602209-A1 OXYTOCIN ANTAGONIST OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-06-22 EP disclosed
EP-0382185-B1 Carbostyril derivatives OTSUKA PHARMA CO LTD (JP) 1994-06-15 EP disclosed
WO-1994001113-A1 OXYTOCIN ANTAGONIST OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1994-01-20 WO disclosed
US-5225402-A Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-07-06 US disclosed
US-5053548-A Containing hydroxy substituents; nervous system disorders OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) 1991-10-01 US disclosed
EP-0382185-A2 Carbostyril derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1990-08-16 EP disclosed
EP-0382213-A2 Biphenyl derivative, nerve cell degeneration repairing or protecting agent and process for preparing a phenyl derivative contained in the agent OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1990-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230320995-A1 IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES PLTP, LNPEP, PLIN3 S1PR2 927/4885S1PR1 743/4885S1PR3 549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.